— · Biotechnology

Eloxx Pharmaceuticals, Inc. (ELOX) Stock

$13.74 -9.49% —: ELOX Healthcare

Valuation

MetricValue
Price$13.74
Market Cap$47.21M
P/E Ratio-9.79
P/B Ratio2.18
P/S Ratio0.00
EPS (TTM)$-5.39
52-Week High$23.40
52-Week Low$8.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.52%
ROA-13.02%
ROCE-17.76%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.08
Current Ratio0.29

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0——$0
Operating Profit$-42.0M$-34.0M——$-6.0M
Net Profit$-67.0M$-36.0M——$-6.0M
EPS$-419.65$-183.15——$-5.39
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$45.0M$21.0M$2.0M$3.0M$5.0M
Total Liabilities$23.0M$32.0M$24.0M$27.0M$17.0M
Cash$43.0M$19.0M$1.0M$0$5.0M
Borrowings$13.0M$13.0M$4.0M$7.0M$1.0M

Latest News

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq PR Newswire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-32.0M$-14.0M$-5.0M$-6.0M
Investing Cash Flow$2.0M$0$0$0$6.0M
Financing Cash Flow$3.0M$9.0M$0$0$9.0M
Net Cash Flow$18.0M$-23.0M$-18.0M$-1.0M$-15.0M
Free Cash Flow$-35.0M$-32.0M$-14.0M$-5.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio-0.11
EV / EBITDA1.32
FCF Yield-20.03%
Quick Ratio3.74
Interest Coverage-222.84
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held26.28%
Institutions Held40.88%
Institutions Float Held55.46%
Institutional HolderSharesReport Date
Activest Wealth Management42026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIOCQBiocept, Inc. $0.00 — -0.01 $525 0.00%
CDXICardax, Inc. $0.00 — 0.00 $80 0.00%
HTGMQHTG Molecular Diagnostics, Inc. $0.00 — 0.00 $221 0.00%
MDVLQMedAvail Holdings, Inc. $0.00 — -0.05 $161 0.00%
MICRDMicron Solutions, Inc. $0.00 — 0.00 $317 0.00%

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. (ELOX) stock trades at $13.74 with a market capitalization of $47.21M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.79, reflecting a net loss over the last twelve months, price-to-book of 2.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.20 and $23.40, and currently trades 41.3% below its 52-week high.

On profitability, Eloxx Pharmaceuticals, Inc. generates a return on equity (ROE) of -42.52% (not meaningful, as shareholders' equity is negative), return on capital employed of -17.76%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.